GLPwatch
MASH (metabolic dysfunction-associated steatohepatitis)
Approved indication
Last updated 2026-05-28 15:46 UTCResearch on semaglutide in the context of MASH (metabolic dysfunction-associated steatohepatitis) includes studies on its effects in mouse models of NAFLD (nonalcoholic fatty liver disease) and evaluations of its safety profile, as well as discussions on its potential mechanisms in MASLD (metabolic dysfunction-associated steatotic liver disease) treatment.
AI summary of the sources below.
Approved GLP-1 drugs (0)
No GLP-1 drug is FDA-approved for mash (metabolic dysfunction-associated steatohepatitis) in our data. Any research below reflects investigational or off-label study.
Research (50)
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
- Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
- Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.
- Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
- Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
- Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
- Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
- Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
- Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
- Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials.
- GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy.
- GLP-1 receptor agonists: a review of head-to-head clinical studies.
- GLP-1 receptor agonists: an updated review of head-to-head clinical studies.
- Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications.
- Recent updates on GLP-1 agonists: Current advancements & challenges.
- Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.
- Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.
- Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).
- Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.
- EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
- Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.
- Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
- Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.
Common questions
- Which GLP-1 drugs are FDA-approved for MASH (metabolic dysfunction-associated steatohepatitis)?
- No GLP-1 drug is currently FDA-approved for mash (metabolic dysfunction-associated steatohepatitis); any use would be off-label or investigational.
- Is there research on GLP-1 drugs for MASH (metabolic dysfunction-associated steatohepatitis)?
- GLPwatch tracks 555 research papers on GLP-1 drugs and mash (metabolic dysfunction-associated steatohepatitis). This research is investigational and does not imply FDA approval.